Protective role of epigallocatechin-3-gallate in NADPH oxidase-MMP2-Spm-Cer-S1P signalling axis mediated ET-1 induced pulmonary artery smooth muscle cell proliferation

  • Jaganmay Sarkar
  • Tapati Chakraborti
  • Animesh Chowdhury
  • Rajabrata Bhuyan
  • Sajal ChakrabortiEmail author
Research Article


The signalling pathway involving MMP-2 and sphingosine-1-phosphate (S1P) in endothelin-1 (ET-1) induced pulmonary artery smooth muscle cell (PASMC) proliferation is not clearly known. We, therefore, investigated the role of NADPH oxidase derived O2.--mediated modulation of MMP2-sphingomyeline-ceramide-S1P signalling axis in ET-1 induced increase in proliferation of PASMCs. Additionally, protective role of the tea cathechin, epigallocatechin-3-gallate (EGCG), if any, in this scenario has also been explored. ET-1 markedly increased NADPH oxidase and MMP-2 activities and proliferation of bovine pulmonary artery smooth muscle cells (BPASMCs). ET-1 also caused significant increase in sphingomyelinase (SMase) activity, ERK1/2 and sphingosine kinase (SPHK) phosphorylations, and S1P level in the cells. EGCG inhibited ET-1 induced increase in SMase activity, ERK1/2 and SPHK phosphorylations, S1P level and the SMC proliferation. EGCG also attenuated ET-1 induced activation of MMP-2 by inhibiting NADPH oxidase activity upon inhibiting the association of the NADPH oxidase components, p47phox and p67phox in the cell membrane. Molecular docking study revealed a marked binding affinity of p47phox with the galloyl group of EGCG. Overall, our study suggest that ET-1 induced proliferation of the PASMCs occurs via NADPH oxidase-MMP2- Spm- Cer-S1P signalling axis, and EGCG attenuates ET-1 induced increase in proliferation of the cells by inhibiting NADPH oxidase activity.


EGCG MMP-2 NADPH oxidase proMMP-2 SMase SPHK S1P 



We greatly acknowledge University Grants Commission, New Delhi for providing Rajiv Gandhi National Fellowship (RGNF) to Jaganmay Sarkar. We are also thankful to the Bioinformatics Infrastructure Facility (BIF), University of Kalyani, West Bengal, India for the computational study.

Compliance with ethical standards

Conflict of interest

Authors declare that there is no conflict of interest.

Supplementary material

12079_2018_501_MOESM1_ESM.docx (19 kb)
ESM 1 (DOCX 18 kb)
12079_2018_501_Fig13_ESM.png (71 kb)
Fig. S1

(PNG 70 kb)

12079_2018_501_MOESM2_ESM.tif (70 kb)
High Resolution (TIF 70 kb)
12079_2018_501_Fig14_ESM.png (148 kb)
Fig. S2

(PNG 148 kb)

12079_2018_501_MOESM3_ESM.tif (130 kb)
High Resolution (TIF 130 kb)
12079_2018_501_Fig15_ESM.png (110 kb)
Fig. S3

(PNG 109 kb)

12079_2018_501_MOESM4_ESM.tif (104 kb)
High Resolution (TIF 104 kb)
12079_2018_501_MOESM5_ESM.docx (13 kb)
ESM 2 (DOCX 12 kb)


  1. Augé N, Maupas-Schwalm F, Elbaz M, Thiers JC, Waysbort A, Itohara S, Krell HW, Salvayre R, Nègre-Salvayre A (2004) Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110:571–578CrossRefGoogle Scholar
  2. Bautista-Pérez R, del Valle-Mondragón L, Cano-Martínez A, Pérez-Méndez O, Escalante B, Franco M (2015) Involvement of neutral sphingomyelinase in the angiotensin II signaling pathway. Am J Physiol Renal Physiol 308:F1178–F1187CrossRefGoogle Scholar
  3. Beswick RA, Dorrance AM, Leite R, Webb RC (2001) NADH/ NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38:1107–1111CrossRefGoogle Scholar
  4. Bhuyan R, Nandy SK, Seal A (2015) An in silico structural insights into Plasmodium LytB protein and its inhibition. J Biomol Struct Dyn 33:1198–1210CrossRefGoogle Scholar
  5. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases. Mol Cell Biochem 253:269–285CrossRefGoogle Scholar
  6. Chakraborti S, Chowdhury A, Kar P, Das P, Shaikh S, Roy S, Chakraborti T (2009) Role of protein kinase C in NADPH oxidase derived O2*(−)-mediated regulation of KV-LVOCC axis under U46619 induced increase in [Ca2+]i in pulmonary smooth muscle cells. Arch Biochem Biophys 487:123–130CrossRefGoogle Scholar
  7. Chakraborti S, Chowdhury A, Chakraborti T (2015) Cross-talk between p38MAPK and Giα in regulating cPLA2 activity by ET-1 in pulmonary smooth muscle cells. Mol Cell Biochem 400:107–123CrossRefGoogle Scholar
  8. Chakraborti S, Sarkar J, Chowdhury A, Chakraborti T (2017) Role of ADP ribosylation factor6- Cytohesin1-PhospholipaseD signaling axis in U46619 induced activation of NADPH oxidase in pulmonary artery smooth muscle cell membrane. Arch Biochem Biophys 633:1–14CrossRefGoogle Scholar
  9. Chakraborti S, Sarkar J, Bhuyan R, Chakraborti T (2018) Role of curcumin in PLD activation by Arf6-cytohesin1 signaling axis in U46619-stimulated pulmonary artery smooth muscle cells. Mol Cell Biochem 438:1–13CrossRefGoogle Scholar
  10. Chaumais MC, Guignabert C, Savale L, Jaïs X, Boucly A, Montani D, Simonneau G, Humbert M, Sitbon O (2015) Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs 15:13–26CrossRefGoogle Scholar
  11. Chelladurai P, Seeger W, Pullamsetti SS (2012) Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J 40:766–782CrossRefGoogle Scholar
  12. Chen QW, Edvinsson L, Xu CB (2009) Role of ERK/MAPK in endothelin receptor signaling in human aortic smooth muscle cells. BMC Cell Biol 3:10–52Google Scholar
  13. Chen J, Tang H, Sysol JR, Moreno-Vinasco L, Shioura KM, Chen T, Gorshkova I, Wang L, Huang LS, Usatyuk PV, Sammani S, Zhou G, Raj JU, Garcia JG, Berdyshev E, Yuan JX, Natarajan V, Machado RF (2014) The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med 190:1032–1043CrossRefGoogle Scholar
  14. Chowdhury A, Sarkar J, Chakraborti T, Pramanik PK, Chakraborti S (2016) Protective role of epigallocatechin-3-gallate in health and disease: a perspective. Biomed Pharmacother 78:50–59CrossRefGoogle Scholar
  15. Das S, Mandal M, Chakraborti T, Mandal A, Chakraborti S (2004) Isolation of MMP-2 from MMP-2/TIMP-2 complex: characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane. Biochim Biophys Acta 1674:158–174Google Scholar
  16. David WW (1978) In biostatistics: A foundation for analysis in health sciences. Wiley, New York, p 219Google Scholar
  17. Deng YT, Lin JK (2011) EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem 59:13318–13327CrossRefGoogle Scholar
  18. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Görlach A (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25:519–525CrossRefGoogle Scholar
  19. Eisinger DA, Ammer H (2009) Down-regulation of c-CbI by morphine accounts for persistent ERK1/2 signaling in delta-opioid receptor-expressing HEK293 cells. J Biol Chem 284:34819–34828CrossRefGoogle Scholar
  20. Feng Z, Chen L, Maddula H, Akcan O, Oughtred R, Berman HM, Westbrook J (2004) Ligand depot: a data warehouse for ligands bound to macromolecules. Bioinformatics 20:2153–2155CrossRefGoogle Scholar
  21. Garanich JS, Pahakis M, Tarbell JM (2005) Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol 288:H2244–H2252CrossRefGoogle Scholar
  22. He S, Prasanna G, Yorio T (2007) Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest Ophthalmol Vis Sci 48:3737–3745CrossRefGoogle Scholar
  23. Hwang KC, Lee KH, Jang Y, Yun YP, Chung KH (2002) Epigallocatechin-3-gallate inhibits basic fibroblast growth factor-induced intracellular signaling transduction pathway in rat aortic smooth muscle cells. J Cardiovasc Pharmacol 39:271–277CrossRefGoogle Scholar
  24. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748CrossRefGoogle Scholar
  25. Kawahara T, Lambeth JD (2007) Molecular evolution of Phox-related regulatory subunits for NADPH oxidase enzymes. BMC Evol Biol 7:178CrossRefGoogle Scholar
  26. Khalil RA (2011) Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension. Curr Mol Pharmacol 4:176–186CrossRefGoogle Scholar
  27. Kim FY, Barnes EA, Ying L, Chen C, Lee L, Alvira CM, Cornfield DN (2015) Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 308:L368–L377CrossRefGoogle Scholar
  28. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH (2016) PubChem substance and compound databases. Nucleic Acids Res 44:D1202–D1213CrossRefGoogle Scholar
  29. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Suzaki Y, Abe S, Hasegawa T, Tamaki T (2002) Antioxidants inhibit endothelin-1 (1-31)-induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1). Biochem Pharmacol 64:1521–1531CrossRefGoogle Scholar
  30. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4:181–189CrossRefGoogle Scholar
  31. Lassegue B, Clempus RE (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285:R277–R297CrossRefGoogle Scholar
  32. Mandal A, Chakraborti T, Das S, Ghosh B, Ghosh A, Chakraborti S (2004) Matrix metalloproteinase-2-mediated inhibition of Na+-dependent Ca+ uptake by superoxide radicals (O2 .-) in microsomes of pulmonary smooth muscle. IUBMB Life 56:267–276CrossRefGoogle Scholar
  33. Mandal A, Chakraborti T, Choudhury R, Ghosh B, Ghosh AN, Das S, Chakraborti S (2005) Role of MMP-2 in inhibiting Na+ dependent Ca2+ uptake by H2O2 in microsomes isolated from pulmonary smooth muscle. Mol Cell Biochem 270:79–87CrossRefGoogle Scholar
  34. Martin-Martin B, Tovell V, Dahlmann-Noor AH, Khaw PT, Bailly M (2011) The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity. Eur J Cell Biol 90:26–36CrossRefGoogle Scholar
  35. Maupas-Schwalm F, Augé N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, Nègre-Salvayre A (2004) The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J 18:1398–1400CrossRefGoogle Scholar
  36. Meyer JW, Schmitt ME (2000) A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett 472:1–4CrossRefGoogle Scholar
  37. Mora-Pale M, Weïwer M, Yu J, Linhardt RJ, Dordick JS (2009) Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorg Med Chem 17:5146–5152CrossRefGoogle Scholar
  38. Newby AC (2006) Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69:614–624CrossRefGoogle Scholar
  39. Peng N, Liu JT, Guo F, Li R (2010) Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells. Life Sci 86:410–415CrossRefGoogle Scholar
  40. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725–738CrossRefGoogle Scholar
  41. Sachinidis A, Skach RA, Seul C, Ko Y, Hescheler J, Ahn HY, Fingerle J (2002) Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins. FASEB J 16:893–895CrossRefGoogle Scholar
  42. Sarkar J, Chowdhury A, Chakraborti T, Chakraborti S (2016) Cross talk between NADPH oxidase-PKCα-p38MAPK and NF-κB-MT1MMP in activating proMMP-2 by ET-1 in pulmonary artery smooth muscle cells. Mol Cell Biochem 415:13–28CrossRefGoogle Scholar
  43. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85CrossRefGoogle Scholar
  44. Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464CrossRefGoogle Scholar
  45. Stenmark KR, Mecham RP (1997) Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59:89–144CrossRefGoogle Scholar
  46. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:L1013–L1032CrossRefGoogle Scholar
  47. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350–4354CrossRefGoogle Scholar
  48. Wang F, Chang Z, Fan Q, Wang L (2014) Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2. Mol Med Rep 9:1085–1089CrossRefGoogle Scholar
  49. Weber AA, Neuhaus T, Skach RA, Hescheler J, Ahn HY, Schrör K, Ko Y, Sachinidis A (2004) Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis. FASEB J 18:128–130CrossRefGoogle Scholar
  50. Wedgwood S, Black SM (2003) Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. Antioxid Redox Signal 5:759–769CrossRefGoogle Scholar
  51. Yu J, Weïwer M, Linhardt RJ, Dordick JS (2008) The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol 6:204–217CrossRefGoogle Scholar
  52. Zhu TT, Zhang WF, Luo P, He F, Ge XY, Zhang Z, Hu CP (2017) Epigallocatechin-3-gallate ameliorates hypoxia-induced pulmonary vascular remodeling by promoting mitofusin-2-mediated mitochondrial fusion. Eur J Pharmacol 809:42–51CrossRefGoogle Scholar

Copyright information

© The International CCN Society 2019

Authors and Affiliations

  • Jaganmay Sarkar
    • 1
  • Tapati Chakraborti
    • 1
  • Animesh Chowdhury
    • 1
  • Rajabrata Bhuyan
    • 1
  • Sajal Chakraborti
    • 1
    Email author
  1. 1.Department of Biochemistry and BiophysicsUniversity of KalyaniKalyaniIndia

Personalised recommendations